Please ensure Javascript is enabled for purposes of website accessibility

Why Ardelyx Stock Is Sinking Today

By Keith Speights - Apr 30, 2021 at 11:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA pushed back its approval decision for the company's lead candidate.

What happened

Shares of Ardelyx (ARDX 0.69%) were sinking 13% lower as of 11 a.m. EDT on Friday. The decline came after the company announced Thursday evening that the U.S. Food and Drug Administration (FDA) is pushing back its review period for tenapanor by three months.

So what

Ardelyx originally hoped for an FDA approval of tenapanor in controlling serum phosphorus in adults with chronic kidney disease (CKD) on dialysis by yesterday. However, the agency requested additional analyses to help it better understand the drug's mechanism of action.

Man wearing coat and tie holding blocks spelling FDA

Image source: Getty Images.

It's understandable why investors reacted negatively to the three-month delay. The news creates some uncertainty about the prospects for tenapanor.

Ardelyx CEO Mike Raab, though, remained optimistic that the drug would still win approval. He thinks that the additional analyses submitted after talking with the FDA "reinforce the extensive clinical evidence" in support of tenapanor. He said in a statement, "We are confident in the comprehensive data set, are well prepared for the launch of tenapanor upon potential approval and are dedicated to bringing this important medicine to patients."

Now what

The next major catalyst for the biotech stock will now come on or before July 29, when the FDA is scheduled to announce its approval decision for tenapanor. Despite the delay in the agency's review, the prospects for approval still seem to be pretty good. Ardelyx's filing was based on three successful late-stage clinical studies that included more than 1,000 patients.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ardelyx, Inc. Stock Quote
Ardelyx, Inc.
$0.59 (0.69%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.